Teleflex Incorporated designs, develops, manufactures, and supplies single-use medical devices for common diagnostic and therapeutic procedures in critical care…
$155.10+1.27%
报价 2026-11-13
市值
$6.15B
EV
$7.01B
PE (TTM)
–
预期 PE (FY2026)
20.2x
52 周区间距高点 -0.8%
$100.34$156.33
筛选结果
pipeline · 2026-11-13Filter✗ 高增长✗ Cheap✗ GARP
does not hit growth, cheap, or GARP pool
爆发潜力
2026-11-13未命中✗ 收入线✗ EPS 线
| 财年 | 收入倍数 | EPS | PE |
|---|---|---|---|
| FY+22027-12 | 1.0x | 7.71 → 10.94（1.4x） | 14.2 |
| FY+32028-12 | 1.1x | 7.71 → 12.04（1.6x） | 12.9 |
毛利率 53% · TTM 收入 $2255M · 基数 EPS 7.71（调整后）
电话会信号
辅助标签Q3 20262026-11-05
扩产上调指引供不应求
指引 上调
信心 4
分析师 3
“We expect 2027 will show higher adjusted margins, lower interest expense, lower share count, and a meaningful step-up in adjusted EPS.”
原文引用（3）
- 扩产：Meaningfully increasing supply will require a significant multiyear effort
- 上调指引：we are increasing our full year adjusted EPS guidance to reflect our third quarter progress
- 供不应求：the first couple of years, they're probably going to take the majority of our capacity
蓝色标签在暴涨研究中略有区分度；悬停查看口径。
研究结论
还没有研究记录。先生成 L2 基本面报告（约 1–3 分钟），结论会显示在这里。
去生成基本面报告 →历史股价
加载中…
事件
0 条 · 随区间与图例筛选该区间内无事件。
同行对比
FMP 同行列表 · 2026-05-16| 公司 | 市值 | 今日 | 预期营收增速 | 毛利率 | PE | EV/EBITDA | P/FCF | 池 |
|---|---|---|---|---|---|---|---|---|
| TFXTeleflex Incorporated | $6.15B | +1.3% | -31.3% | 53.3% | – | 63.6x | 15.9x | |
| PCVXVaxcyte, Inc. | $10.03B | -2.0% | +4900.0% | 0% | – | – | – | |
| TGTXTG Therapeutics, Inc. | $9.75B | -0.1% | +61.4% | 83% | 15.5x | 50.3x | 560.9x | |
| KRYSKrystal Biotech, Inc. | $9.05B | -0.1% | +28.4% | 92.6% | 35.3x | 40.7x | 29.2x | |
| ALKSAlkermes plc | $7.9B | +0.1% | – | 86.6% | 55.6x | 35.6x | – | |
| BLCOBausch + Lomb Corporation | $7.54B | -0.2% | +8.2% | 60.5% | – | 17.6x | 29.5x | |
| ARWRArrowhead Pharmaceuticals, Inc. | $6.75B | +1.3% | -28.9% | 100% | – | – | – | |
| PTCTPTC Therapeutics, Inc. | $5.3B | +0.2% | -28.6% | 92.4% | – | 33.3x | – | |
| MMSIMerit Medical Systems, Inc. | $5.19B | -0.1% | +8.4% | 48.7% | 31.5x | 13.5x | 25.4x | |
| 同行中位数 | – | – | +8.4% | 84.8% | 33.4x | 34.5x | 29.3x |
研究全文
L2 基本面 memo
尚无基本面 memo
点击「生成基本面报告」——基于最新 filings、电话会纪要与分析师共识生成 L2 memo。
财务报表
暂无季度数据（首次研究运行后填充）。